Us Bancorp \De\ Pacira Bio Sciences, Inc. Transaction History

Us Bancorp \De\

$78.3 Billion
Q2 2025

A detailed history of Us Bancorp \De\ transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 2,087 shares of PCRX stock, worth $51,778. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,087

Previous 2,270 8.06%

Holding current value

$51,778

Previous $56,000 12.5%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 23, 2025	SELL	$22.91 - $27.14 $4,192 - $4,966	-183 Reduced 8.06%	2,087 $49,000
Q1 2025 May 08, 2025	BUY	$18.33 - $27.25 $9,843 - $14,633	537 Added 30.99%	2,270 $56,000
Q4 2024 Feb 05, 2025	SELL	$15.3 - $20.33 $3,580 - $4,757	-234 Reduced 11.9%	1,733 $32,000
Q3 2024 Oct 28, 2024	SELL	$11.7 - $28.46 $98,771 - $240,259	-8,442 Reduced 81.1%	1,967 $29,000
Q2 2024 Aug 06, 2024	SELL	$25.5 - $31.51 $33,991 - $42,002	-1,333 Reduced 11.35%	10,409 $297,000
Q1 2024 May 07, 2024	SELL	$27.7 - $35.48 $25,373 - $32,499	-916 Reduced 7.24%	11,742 $343,000
Q4 2023 Feb 09, 2024	BUY	$26.32 - $34.31 $42,243 - $55,067	1,605 Added 14.52%	12,658 $427,000
Q3 2023 Nov 03, 2023	BUY	$30.68 - $40.09 $20,371 - $26,619	664 Added 6.39%	11,053 $339,000
Q2 2023 Aug 09, 2023	SELL	$36.12 - $47.5 $33,699 - $44,317	-933 Reduced 8.24%	10,389 $416,000
Q1 2023 May 09, 2023	SELL	$35.53 - $43.38 $23,378 - $28,544	-658 Reduced 5.49%	11,322 $462,000
Q4 2022 Feb 13, 2023	SELL	$38.19 - $57.45 $38,762 - $58,311	-1,015 Reduced 7.81%	11,980 $462,000
Q3 2022 Oct 27, 2022	SELL	$51.24 - $58.89 $63,742 - $73,259	-1,244 Reduced 8.74%	12,995 $692,000
Q2 2022 Aug 01, 2022	SELL	$51.49 - $81.64 $134,285 - $212,917	-2,608 Reduced 15.48%	14,239 $830,000
Q1 2022 May 11, 2022	BUY	$60.03 - $76.49 $36,858 - $46,964	614 Added 3.78%	16,847 $1.29 Million
Q4 2021 Feb 11, 2022	BUY	$47.97 - $62.21 $34,538 - $44,791	720 Added 4.64%	16,233 $977,000
Q3 2021 Nov 10, 2021	BUY	$54.64 - $61.3 $95,838 - $107,520	1,754 Added 12.75%	15,513 $869,000
Q2 2021 Aug 05, 2021	BUY	$59.18 - $69.99 $32,489 - $38,424	549 Added 4.16%	13,759 $834,000
Q1 2021 Apr 28, 2021	SELL	$59.31 - $78.82 $14,649 - $19,468	-247 Reduced 1.84%	13,210 $926,000
Q4 2020 Feb 04, 2021	BUY	$50.47 - $66.26 $56,728 - $74,476	1,124 Added 9.11%	13,457 $804,000
Q3 2020 Nov 10, 2020	BUY	$51.97 - $63.0 $141,722 - $171,801	2,727 Added 28.39%	12,333 $741,000
Q2 2020 Aug 07, 2020	BUY	$30.8 - $52.47 $120,181 - $204,737	3,902 Added 68.41%	9,606 $504,000
Q1 2020 May 13, 2020	SELL	$28.4 - $50.7 $1,476 - $2,636	-52 Reduced 0.9%	5,704 $191,000
Q4 2019 Feb 04, 2020	BUY	$36.31 - $46.83 $129,154 - $166,574	3,557 Added 161.76%	5,756 $261,000
Q3 2019 Nov 08, 2019	SELL	$35.66 - $44.99 $77,524 - $97,808	-2,174 Reduced 49.71%	2,199 $84,000
Q2 2019 Aug 13, 2019	BUY	$36.57 - $47.97 $13,713 - $17,988	375 Added 9.38%	4,373 $190,000
Q1 2019 May 08, 2019	BUY	$36.47 - $42.17 $4,266 - $4,933	117 Added 3.01%	3,998 $152,000
Q4 2018 Feb 13, 2019	BUY	$41.31 - $52.16 $17,969 - $22,689	435 Added 12.62%	3,881 $167,000
Q3 2018 Nov 01, 2018	SELL	$32.85 - $52.0 $85,147 - $134,784	-2,592 Reduced 42.93%	3,446 $169,000
Q2 2018 Aug 08, 2018	BUY	$27.5 - $39.8 $48,015 - $69,490	1,746 Added 40.68%	6,038 $194,000
Q1 2018 May 08, 2018	BUY	$29.98 - $46.35 $44,999 - $69,571	1,501 Added 53.78%	4,292 $134,000
Q4 2017 Feb 02, 2018	BUY	$31.85 - $46.95 $3,280 - $4,835	103 Added 3.83%	2,791 $127,000
Q3 2017 Nov 13, 2017	BUY	$35.7 - $39.5 $95,961 - $106,176	2,688	2,688 $101,000

Others Institutions Holding PCRX

# of Institutions

261

Shares Held

51.6M

Call Options Held

157K

Put Options Held

139K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $1.14B
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account